{'fraction_non_alphanumeric': 0.036544850498338874, 'fraction_numerical': 0.029900332225913623, 'mean_word_length': 4.821256038647343, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Olaparib Quantification in Human Plasma for Clinical Purposes using High-Performance Liquid Chromatography with UV detector

A simple, sensitive and accurate HPLC-UV detection method for the determination of olaparib in human plasma samples was developed. Separation was successfully achieved using an YMC C18 reverse phase column (250 × 4.6 mm i.d.; 5 μm) under isocratic mobile phase conditions consisting of methanol-0.1 % orthophosphoric acid (60:40, v/v) and ultra-violet detection was achieved at 220 nm. Extraction of the target compounds was completed using liquid-liquid extraction technique. No endogenous substances were found to interfere with the peaks of drug and internal standard. Good linearity (r2 > 0.99) was achieved for the concentration range of 100-5000 ng/mL and detection limit was 20 ng/mL. The Intra and Inter-day precision and accuracy were found to be within acceptable limits (<15 %). The overall recovery for olaparib was found to be 50.44 %. Stability data revealed that the drug was stable in plasma under various test conditions. Matrix effects were not observed. The present method was effectively implemented to determine the concentration of olaparib in human plasma.